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Background: Simultaneous pancreas kidney transplantation (SPK), pancreas transplantation alone (PTA) or pancreas
transplantation after kidney (PAK) are the only curative treatment options for patients with type 1 (juvenile) diabetes
mellitus with or without impaired renal function. Unfortunately, transplant waiting lists for this indication are
increasing because the current organ acceptability criteria are restrictive; morbidity and mortality significantly
increase with time on the waitlist. Currently, only pancreas organs from donors younger than 50 years of age and
with a body mass index (BMI) less than 30 are allocated for transplantation in the Eurotransplant (ET) area.
To address this issue we designed a study to increase the available donor pool for these patients.
Methods/Design: This study is a prospective, multicenter (20 German centers), single blinded, non-randomized,
two armed trial comparing outcome after SPK, PTA or PAK between organs with the currently allowed donor
criteria versus selected organs from donors with extended criteria. Extended donor criteria are defined as organs
procured from donors with a BMI of 30 to 34 or a donor age between 50 and 60 years. Immunosuppression is
generally standardized using induction therapy with Myfortic, tacrolimus and low dose steroids. In principle, all
patients on the waitlist for primary SPK, PTA or PAK are eligible for the clinical trial when they consent to possibly
receiving an extended donor criteria organ. Patients receiving an organ meeting the current standard criteria for
pancreas allocation (control arm) are compared to those receiving extended criteria organ (study arm); patients are
blinded for a follow-up period of one year. The combined primary endpoint is survival of the pancreas allograft and
pancreas allograft function after three months, as an early relevant outcome parameter for pancreas transplantation.
Discussion: The EXPAND Study has been initiated to investigate the hypothesis that locally allocated extended
criteria organs can be transplanted with similar results compared to the currently allowed standard ET organ
allocation. If our study shows a favorable comparison to standard organ allocation criteria, the morbidity and
mortality for patients waiting for transplantation could be reduced in the future.
Trial registration: Trial registered at: NCT01384006
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Patients with type 1 (juvenile) diabetes mellitus generally
suffer from long-term complications, most of which are
related to vascular disease. Associated nephropathy can
lead to dialysis with its own major risk factors for cardio-
vascular disease and a low quality of life. Simultaneous
pancreas kidney transplantation (SPK) or pancreas trans-
plantation after kidney (PAK) are the only curative treat-
ment options for type 1 diabetic patients with impaired
kidney function [1,2]. The aim of SPK is to optimize blood
sugar control, prevent retinopathy progression and reduce
other cardiovascular diseases, thereby restoring life quality
and length [3-5]. Indeed, if SPK can be done before the pa-
tient requires dialysis, the positive effects are even more
dramatic [6,7]. For instance, progressive retinopathy is
halted or even reversed after SPK [8] and PAK [9], and
motor and autonomous nerve functions improve [10].
Pancreas transplantation alone (PTA) is restricted to
patients with good renal function who suffer from brittle
diabetes or frequent hypoglycemia; this is the only treat-
ment option allowing non-uremic patients with brittle dia-
betes long-term insulin-independency.
Waitlists are constantly increasing in the Eurotransplant
(ET) area. In 2000 there were 195 people on the waitlist
for pancreas or islet cell transplantation, with a total of
331 transplantations performed in that year. In 2010 the
waitlist increased to 337 patients, but only 249 transplan-
tations were possible. Thus, time on the waitlist in
Germany almost doubled within the last ten years and is
now close to two years (data provided by ET), leading to a
significantly worse outcome and higher morbidity for the
patients. One major reason for this decline may be the fact
that – with constantly increasing mean donor age - a large
number of pancreas allografts potentially eligible for trans-
plantation were excluded by the ET pancreas allocation
system (EPAS) until December 2011. Those criteria ex-
cluded donors older than 50 years and those with a body
mass index (BMI) ≥30 (ET Manual Version 26 May 2009).
As the average age of a post-mortal organ donor in the ET
area is now 58 years, donor selection by age has been a
major factor contributing to the current donor pancreas
shortage. In Germany (year 2009), the total number of
deceased organ donors was 1,217. However, only 407 do-
nors were at an acceptable age of < 50 years. Altogether,
594 patients were not even screened for pancreas donation
due to age, regardless of all other medical conditions.
In addition, approximately 13% of potential donors
were not eligible for pancreas donation due to the
BMI restriction (data provided by Deutsche Stiftung
für Organtransplantation e.V. (DSO)). Moreover, in
the ET-area pancreas grafts are allocated without local
priority, frequently leading to rather long ischemic
times due to transportation issues. In summary, be-
cause of the shortage of organ donors there is acritical need to use more of the available pancreas
grafts for transplantation [11].
Currently, available retrospective data from centers out-
side of the ET area suggest a similar outcome after trans-
plantation using extended criteria organs; however, there
is no prospective controlled trial addressing this issue.
Therefore, the aim of our multicenter trial is to investigate
the hypothesis that organs from donors 50 to 60 years old
or with a BMI higher than 30, using local allocation with
shorter ischemic times, can be transplanted with similar
results compared to the standard criteria organs. The po-
tential benefit for the patient who agrees to be trans-
planted with an extended donor criteria (EDC) pancreas
(simultaneously with a standard kidney from the same
donor) is a reduced waiting time with increased survival
and life quality. This could mean that patients will be free
from dialysis and insulin therapy earlier than presently
expected in this region. We suggest that all pancreas
transplantation programs in Germany (later, in the ET
area) will benefit from this allocation system, as these
EDC allografts will be available in addition to the pancreas
grafts allocated currently, thereby increasing the pool of
organs for pancreas transplantation. If the EXPAND study
shows that EDC pancreases can be used with a regional
allocation system without additional risk, this will poten-
tially lead to a readjustment of pancreas allocation towards
a regional allocation and transplantation system, which
might achieve better results for more pancreas transplant
recipients.
Methods/Design
Objectives and study concept
This study is a prospective, multicenter, single blinded,
non-randomized, two-armed trial comparing outcome
after SPK, PTA or PAK transplantation of organs with
the currently allowed standard donor criteria to organs
of donors with extended criteria. Extended criteria
means a BMI 30 to 34 or donor age between 50 and 60
years. The enrollment phase will be three years with a
follow-up period of one year. The primary endpoints are
pancreas allograft survival and function at three months
after transplantation. Our hypothesis is that pancreas or-
gans of donors with extended criteria if transplanted re-
gionally will have a similar function compared to organs
with the currently allowed criteria. Overall survival, kid-
ney and pancreas allograft function and survival, inci-
dence of dialysis, post transplant insulin requirement, as
well as infections and cardiovascular events will be
assessed as secondary endpoints during the one-year
follow-up. Secondary endpoints additionally include a
quality of life assessment, biopsy proven acute rejections
and time on the waitlist. In this study, patients who re-
ceive a standard criteria organ will be included in the
control arm, and an equal number of patients who
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(Figure 1).
The EXPAND Study is an investigator-initiated trial
for which the University Hospital Regensburg is the
sponsor. Funding assistance is through grants provided
by Astellas (Munich, Germany) and Novartis GmbH
(Nürnberg, Germany).
Allocation system
The allocation algorithm for potential deceased pancreas
donors is regulated and defined in the ET handbook, sec-
tion 7.1: Pancreas Allocation Algorithms. One reason for
the decline in availability of pancreas allografts is the strict
exclusion criteria set by the EPAS. As already mentioned,
the main cut-off criteria for donors are age > 50 years or
BMI ≥ 30 (current, standard criteria). For organs within
the current criteria, allocation is performed according to
HLA matching to the recipient, urgency status of recipi-
ent, waitlist time, and so on. Local distribution aspects are
not part of the current allocation system, resulting in rela-
tively long cold ischemic times in many cases.
For the EXPAND Study to allow allocation of EDC or-
gans (age 50 to 60 or BMI 30 to 34) all responsible na-
tional and European authorities have been included in the
development of an alternative rescue allocation system.
ET and the German Medical Legislation Authorities, as
well as the national Organ Procurement Organization
(DSO) have been actively involved. In December 2010, ET
established a rescue allocation system for extended criteria
pancreas donors for the purposes of the EXPAND Study.
All deceased potential pancreas donors are screened
for eligibility with regard to the current allocation al-Figure 1 Inclusion scheme.gorithm. Organs meeting the standard criteria will be
allocated to control arm patients. Other potential organs
of donors with EDC who are between 50 and 60 years of
age or have a BMI of 30 to 34 are now allocated according
to the so-called ‘Beschleunigtes Vermittlungsverfahren’
(‘rescue allocation’), which has recently been implemented
in the ET allocation system for extended pancreas use in
Germany as part of this study. These organs are allocated
only regionally to ensure a cold ischemic time of less than
12 hours. Other donor criteria are used to identify poten-
tial donors such as serum amylase or lipase, time on the
ICU for the donor or use of vasoactive drugs; the risk/
benefit assessment is made at the discretion of the trans-
plant surgeons in both groups, with no distinct cut off line
for those parameters.
Organ procurement and transplantation procedures
are carried out according to internationally defined
standards of organ procurement and pancreas
transplantation. In Germany, arterial perfusion with
histidine-tryptophan-ketoglutarate (HTK) solution is
routinely performed and a backtable perfusion through
the portal vein is recommended. In the case of an EDC
organ, the regional allocation is performed with the
following rules:
1. Regional centers receive organ offers in a rotation
pattern. This means that every center receives
(in a pre-defined fashion) sequential organ offers
independent of the size of their waiting list or
number of pancreas transplantations per year.
2. In case the first center rejects the offer, the organ is
automatically offered to the procuring site.
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recipient of the same ABO blood type, with a negative
cross match, in their center for the transplantation. These
rules aim for a fair local distribution, support small and
very dedicated centers, and attempt to minimize cold-
ischemic time.
Study population
All patients on the waitlist for primary SPK, PTA or
PAK meeting the inclusion criteria are eligible for the
trial.
Inclusion criteria
Adult patients >18 years of age eligible for primary SPK,
PTA or PAK standard or extended criteria organ alloca-
tion are included in the study when informed consent is
given prior to transplantation. In addition, the crossmatch
testing must be negative.
Exclusion criteria
Patients with malignant diseases within the past five years
prior to transplantation (except for squamous cell carcin-
oma and basal cell carcinoma of the skin) are excluded.
Patients who are listed for pancreas re-transplantation are
excluded, as well as women of childbearing potential not
willing to take contraception. Also, patients with a psycho-
logical, familial, sociological or geographic condition po-
tentially hampering compliance with the study protocol
and follow-up schedule, and patients under guardianship
(for example, individuals who are not able to freely give
their informed consent) are excluded.
Consent
A study investigator will contact patients on the waitlist
to introduce the study and associated procedures. An
important part of the consent procedure is that the pa-
tient agrees to receive an extended criteria organ. When
informed consent is given, patients are asked again for
their consent at the time of transplantation. A patient is
only eligible for an extended criteria organ when written
and signed informed consent is given.
Procedures to minimize bias
An important issue of this study was not only to confirm
the safe use of EDC organs, but also to assess the quality
of life experienced by the patient. To allow an unpreju-
diced evaluation, patients are blinded to their group inclu-
sion. Because the transplant surgeon needs to consider all
risk factors associated with the offered organ in relation to
the patient, a double-blind set-up was not deemed appro-
priate. Additionally, randomization is not possible since
inclusion into each study arm depends on the criteria
(standard versus extended) of the organ, which is available
for the patient at the time of transplantation.Interventions
Pre- and intraoperative data
Baseline data are documented, including demographics,
medical history, current medication, liver and renal func-
tion, as well as history of renal replacement therapy and
assessment of the quality of life. Intraoperative data (warm
and cold ischemic times, blood-loss, requirement for
blood products, incision to suture times) and donor data
(age, serum-sodium, gamma- glutamyl transpeptidase,
BMI, infectious status) are also documented.
Treatment regimen
Organ procurement and transplantation procedures are
carried out according to internationally defined standards
of organ procurement [12] and pancreas transplant proce-
dures [1]. This trial is not aimed at establishing new
immunosuppressive strategies, but rather to collect data
prospectively in patients with EDC pancreas criteria, local
allocation, and reduced cold-ischemic time in order to
enlarge the donor pool for pancreas transplantation. To
obtain comparable data, we strongly advocate the use of
standardized immunosuppressive regimens in this study.
We generally recommend the use of induction therapy
with depleting or non-depleting antibodies [13]. Further
maintenance therapy is normally performed with a
combination therapy of tacrolimus (Prograf®, Astellas
Pharma GmbH, Munich, Germany) (center specific
trough levels), primarily MMF i.v. (CellCept®, Roche Pharma
AG, Grenzach-Wyhlen, Germany) and later MPA oral
(Myfortic®, Novartis Pharma GmbH, Nürnberg, Germany)
(enteric-coated MPA). Steroids can be used according
to center-specific protocols. To reduce pro-diabetic ef-
fects, early withdrawal of steroids (for example, two weeks
after transplantation) is recommended [14]. Patients
within the study will receive a combination immunosup-
pressive therapy of tacrolimus, MPA and steroids with
early steroid withdrawal. Apart from this, all patients will
be treated according to center specific standards. Trans-
plant biopsies are not included within this protocol.
Follow-up
After transplantation, all patients will have follow-up
study visits at days 7 and 14, and after 1, 3, 6, 9 and 12
months. Data collected in this study include only clinical
and laboratory results that are routinely recorded any-
way; investigations and examinations will not exceed the
normal clinical standard at the participating sites. Docu-
mentation includes data on graft survival, graft function
(laboratory values), incidence of clinically-diagnosed and
biopsy-proven acute rejection (kidney and/or pancreas),
severity of rejection (histological grade), changes in glu-
cose metabolism, insulin requirement, need for dialysis,
drug adverse events, infectious complications, cardiovas-
cular incidents, general physical condition, and patient
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life assessment will be performed (standardized ques-
tionnaire SF-12). During recruitment and follow-up of
patients, regular monitoring of safety and endpoint data
is performed according to good clinical practice (GCP)
guidelines.
Clinical sites
The study is planned as a multicenter (up to 20 sites)
trial within Germany. As transplantation numbers in
Germany are low for single centers, multiple sites are
necessary to achieve the required patient number within
a reasonable amount of time.
Safety aspects
The Ethics Committee of the University Regensburg ap-
proved the study protocol on 17 December 2010 (number
10-101-0243), with approval following for all other partici-
pating sites. The study complies with the Declaration of
Helsinki and the principles of GCP guidelines. Informed
consent is obtained from each patient in written form
while being on the waitlist and again prior to transplant-
ation. A medical doctor familiar with the study informs
the patient about the nature, duration and possible conse-
quences of the trial. Patient safety and all potential threats
for the patients are monitored once a year by an inde-
pendent data monitoring committee. Qualified personnel
at the sponsor site continuously review safety data, includ-
ing adverse events and serious adverse events.
Sample size calculation
The sample size was calculated by means of the primary
endpoint, pancreas allograft survival rate after three
months, on the assumption that a rate of 80% can be
expected [15,16] whereas, the minimal accepted survival
rate is 65%. The limit of 65% is based on the maximally
acceptable lower organ survival rate, as agreed by the
clinical trial centers. The significance level of alpha (one-
sided) was set to 0.05 and beta was set to 0.20. This is in
accordance with the estimation of a one-sided 95% con-
fidence interval for the survival rate after three months.
Assuming that a one-sided, binomial hypothesis test
with a target significance level α = 0.05 and a target
power 1−β = 0.80 will be used for analysis, 55 patients
with an extended donor pancreas allograft should be
enrolled in this study. A sample size of 55 patients with
extended donor pancreas allografts achieves 80% power
to distinguish between the two proportions 65% (p0) and
80% (p1) using a one-sided, binomial hypothesis test
with a target significance level of 0.05. The control
group should be of equal size for analyzing the second-
ary endpoints. Assuming a maximal dropout rate of
10%, a total of 120 patients will be required. Sample size
was estimated based on exact binomial probabilities andcalculation was performed using NCSS-PASS 2000. No
power analysis for secondary endpoints was done.
Statistical analysis
A one-sided, binomial hypothesis test with a target sig-
nificance level α = 0.05 and a target power 1−β = 0.80
will be used for analysis of the primary endpoint. The
primary analysis will be based on the intention-to-treat
(ITT) analysis set. However, a sensitivity analysis will be
done on a per-protocol (PP) analysis set. The latter
serves to assess the robustness of the results. All safety
data will be analyzed by means of the safety population.
For the secondary endpoints the treatment group will be
compared to the control group, and all statistical tests
will be two sided and will be done at the 0.05 signifi-
cance level. The exact analyzing strategies of all second-
ary endpoints will be further specified in a Statistical
Analysis Plan, which will be finalized prior to database
lock. The statistical analysis will be done by the Center for
Clinical Studies at the University Hospital Regensburg.
Current status
The first center was initiated in July 2011 and the first
patient was enrolled on 26 July 2011. The last two
centers have been initiated in January 2013. Of all 20
German centers, 12 centers are actively recruiting pa-
tients by now.
Discussion
A recent single center study showed a 20-year survival
rate of 58% after SPK; in comparison, the 20-year sur-
vival rate was 0% for patients who stayed on insulin
therapy and dialysis [1]. An analysis of the Organ Pro-
curement and Transplantation (OPTN) registries includ-
ing 12,478 patients also reveals remarkable advantages
of SPK transplantation. Data showed only a 58% four-
year survival rate for patients on the waitlist, compared
to a four-year survival rate of 90% after SPK [17]. To put
this in perspective, the survival time on the waiting list
is worse than for patients with stage 3 colon cancer [18].
Therefore, all patients with type 1 diabetes and impaired
kidney function should be transplanted as soon as
possible.
With this stark realization in times of organ shortage,
new strategies to expand the donor pool are needed.
Success in this regard has been realized with other organ
transplants. For instance, the use of ‘marginal’ or ‘ex-
tended’ criteria donor organs is well established now,
such as the so-called European Senior Donor Program
for kidneys. Here, the potential higher risk associated
with an older organ was compensated by the benefit of a
short ischemic time through a change in the allocation
system to only regional allocation [19,20]. Regarding
pancreas transplantation, there are different factors that
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pool. There are data from other allocation areas through-
out the world (United Network for Organ Sharing
(UNOS) or UK) that a good overall outcome after pan-
creas transplantation can be achieved with donors exceed-
ing the standard allocation criteria as currently defined by
ET, if the cold ischemic time is kept short. In Great
Britain, a local retrieval and allocation system was
established in 2000 [21], resulting in a steep increase in
pancreas transplantation [22,23] via extensive use of ex-
tended pancreas donors. These extended criteria avoid the
donor BMI restriction and accept donors with an age be-
tween 8 and 68 years. Meanwhile 350 SPK and PTA were
transplanted with an excellent one-year pancreas survival
of 91%, kidney survival of 95% and a patient survival of
96% [24].
A retrospective analysis of OPTN registries in the US
compared 8,850 SPK from young donors versus 776 SPK
from donors > 45 years. The analysis showed that pa-
tients transplanted earlier using an organ from an older
donor have similar survival rates when compared to
those recipients waiting for a young donor for more than
1.5 years [25]. Good results were also achieved with ex-
tended and older pancreas donor organs in the US
[16,26-30]. However, it is important to note that these
data are only available from retrospective database ana-
lyses. Nonetheless, to keep ischemia times short, high
volume centers outside of the ET zone use a regional al-
location system [1-3,31-33].
For Germany, the existing allocation system has led to
long ischemic times due to transportation issues; this
fact is reflected in poorer outcomes in Germany [34,35]
compared to high volume centers in the UK [24], USA
[1,3,36] and Italy [15,32]. To address this problem, with
the EXPAND study we are aiming to obtain prospective
high-level evidence for changing our allocation system
to regional-based allocation. It is expected that the po-
tential higher risk of delayed graft function and pancrea-
titis of EDC organs [37] will be compensated by reduced
ischemic times. The EXPAND study was developed with
the aim of utilizing otherwise discarded EDC organs
through this allocation strategy, leading to a significantly
improved overall outcome in the ET zone. Moreover,
this is the first study to evaluate the results of trans-
plantation of EDC pancreas organs in a prospective clin-
ical trial.
Interestingly, we can already report that after implemen-
tation of the rescue allocation system, transplant centers
throughout Germany started to use EDC organs. This has
led to an increase in transplant numbers - as had been an-
ticipated when designing the study. Importantly, however,
this does not mean that the quality of the transplanted or-
gans and the success of this strategy are assured. This is
what we expect to determine in our current trial and whatthe authorities want to see before extending the rescue al-
location system to the whole ET area.
Conclusions
The EXPAND study is the first prospective trial compar-
ing and evaluating the outcome of standard criteria de-
ceased donor pancreas organs to extended criteria organs.
If our hypothesis, that EDC organs can be used with a
similar outcome without additional risk for the patient is
correct, the pancreas donor pool will successfully be ex-
panded in the ET region. This will lead to more transplan-
tations and shorter times on the waitlist with significantly
reduced morbidity, increased life expectancy and better
quality of life for many patients.
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